Therapeutic co-administration of TGF-β-blocking reagents and anti-PD-L1 antibodies reduced TGF-β signaling in stromal cells, facilitated T-cell tumor penetration, and promoted tumor regression (109). This evidence concerns the gene CD274 and neoplasm.